ClinicalTrials.gg
RecruitingNCT07706127Updated Jul 15, 2026

mHealth to Improve Medication Adherence Among Latina Breast Cancer Patients Experiencing Non-Medical Drivers of Health

An interventional study of HT Helper app use plus patient navigation support and Patient Navigation support alone in Treatment Adherence, sponsored by The University of Texas Health Science Center at San Antonio. Recruiting at 1 site in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-15.

Sponsored by The University of Texas Health Science Center at San Antonio · Not applicable, Interventional, and Supportive care

How we know

From the registry’s dates

  • Registered 9 months after the study started (first participant enrolled Sep 2025, registered Jul 2026).
  • Started Sep 2025; still recruiting 1 year 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
159
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 75 studies in Treatment Adherence and Compliance with a site in United States — 12 open to participants now, 15 under way, none of them phase 3. Treatment Adherence and Compliance · United States.

Planned enrollment
19th of 70
159 · median 66
Started
2025
with 1 other
No phase
58 of 75
8 open now
Primary completion
2028-04
later than 11 of 14 live
Registered
72nd of 75
by date

Among the 75 studies in Treatment Adherence and Compliance with a site in United States, this one is the 19th largest by planned enrollment of the 70 interventional ones that give a count, is one of 2 that started in 2025, is one of 58 with no phase, reaches primary completion later than 11 of the 14 other live ones, and was the 72nd registered.

Treatment Adherence and Compliance

353 studies on the registry are indexed under Treatment Adherence and Compliance; 108 are open to participants now.

Browse Treatment Adherence and Compliance studies →

Open to participants now

12 of the 75 studies in Treatment Adherence and Compliance with a site in United States are open now. Recruiting first, the newest first:

6 more — sign in →

All 12 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 59 Treatment Adherence and Compliance studies recruiting now, 46 (78%) set no upper age limit and 12 (20%) stop at 75 or younger; 7 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 75 studies in Treatment Adherence and Compliance with a site in United States, or all of them as a file.
02

Study summary

Background: Hormonal therapy (HT) is highly effective for nearly all breast cancer patients with hormone receptor-positive tumors, which are about 80% of all breast cancer diagnoses. Long-term use of HT reduces cancer recurrence rates and cuts the risk of mortality nearly in half during the second decade after diagnosis. Despite proven benefits, 33% of women who are prescribed HT do not take it as prescribed (\<80% take their daily dosage). Latina patients are disproportionately affected by non-medical drivers of health (NMDoH) that keep them from adhering to HT and are at higher risk of breast cancer recurrence and mortality.

Objective: The goal of this 4-year randomized controlled study is to assess the effectiveness of the bilingual, culturally tailored, interactive HT Helper App, in combination with patient navigation (PN), on improving adherence to HT among Latina breast cancer patients experiencing any NMDoH barriers, such as income, health insurance, education, health literacy, and language, that impact their medication adherence. This theory-based intervention will increase patient education, enhance self-efficacy, facilitate communication with the medical team and coordination of resources to address NMDoH barriers, and help patients develop self-care skills for optimal adherence to HT, ensuring patients the most equitable treatment outcomes possible, including improvement in quality of life, survival, and life expectancy.

Specific Aims/Hypothesis: 1) Conduct a 3-group randomized study to assess the effectiveness of the HT Helper App + PN vs. PN alone vs. usual care, on HT adherence; and 2) Assess the effect of each study condition on patient self-efficacy to identify side effects, use self-care to manage side effects, and communicate with the medical team. We hypothesize that the HT Helper App + PN and the PN alone groups will have greater rates of HT adherence and higher patient self-efficacy than the usual care group; with the HT Helper App + PN achieving better results than both PN alone and the usual care groups.

Study Design. The proposed study involves a parallel 3-group randomized controlled trial with 5-time assessments (baseline, 3, 6, 12, and 18 months) and will enroll 159 breast cancer patients who are prescribed HT and are attending the breast clinic at the Mays Cancer Center at UT Health San Antonio. Intervention components are based on Social Cognitive Theory and elements of Motivational Interviewing.

Cancer Relevance. This innovative multi-level intervention will improve adherence to HT by addressing NMDoH and promote equitable breast cancer outcomes, including reduced recurrence and improved quality of life, overall survival, and life expectancy among underserved Latina patients. The anticipated outcome is a scalable, evidence-based, and easily disseminated intervention with potentially broad use to patients using oral anticancer medications.

03

Conditions studied

  • Treatment Adherence

Keywords

  • phone app
  • breast cancer hormone therapy
  • treatment adherence
  • Latinas
  • non-medical drivers of health
  • patient navigation
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

English- or Spanish-speaking Latina patients aged 18 and older who:

a) are diagnosed with hormone receptor-positive breast cancer and prescribed HT; b) within 1 to 24 months of starting HT; c) are experiencing any NMDoH by the Avanzando Center NMDoH Screener; d) are able to read; e) own a smartphone and are able to send and receive text messages and access the Internet; and f) are able to provide to participate in the study.

Exclusion criteria

Exclusion Criteria:

Not meeting the criteria above, or patients who:

a) are not Latina and are younger than 18 years; b) are not receiving HT treatment; c) with more than 24 months of starting treatment; d) do not experience any NMDoH by the Avanzando Center NMDoH Screener; e) are unable to read; f) do not own a smartphone and are unable to send and receive text messages and access the Internet; g) are unable to respond to text messages and questions or unable to download the study app; h) are unable to provide due to a mental, emotional, or physical handicap that keeps them from understanding the consent information; i) are unable to see the app and study materials and videos (i.e., are blind, deaf); and j) currently participating in a psychosocial intervention trial or individual/group psychotherapy.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
159 participants (estimated)

Study arms

  • Experimental
    Group 1: HT Helper App + Patient Navigation

    Behavioral: HT Helper app use plus patient navigation support · Other: Usual Care

  • Experimental
    Group 2: Patient Navigation Alone

    Behavioral: Patient Navigation support alone · Other: Usual Care

  • Other
    Group 3: Usual Care

    Control group

    Other: Usual Care

Interventions

  • BehavioralHT Helper app use plus patient navigation support

    HT Helper app plus patient navigation support to promote hormone therapy adherence among breast cancer patients experiencing NMDoH barriers

  • BehavioralPatient Navigation support alone

    Patient navigation support to address NMDoH barriers impacting hormone therapy adherence

  • OtherUsual Care

    Usual care provided to patients who are prescribed hormone therapy and attend the Breast Clinic at the Mays Cancer Center

06

What researchers measure

Primary outcomes

  1. Adherence to hormone therapy

    Adherence to HT, defined as the percentage of doses taken as prescribed, with optimal adherence considered at ≥80%.

    Time frame: From enrollment to end of the intervention at 18 months

  2. Self-efficacy for Appropriate Medication Use Scale (SEAMS)

    Self-efficacy for medication adherence will be measured using the Self-Efficacy for Appropriate Medication Use Scale (SEAMS), a validated 13-item instrument with three-point Likert scale response options ranging from 1=not confident to 3=very confident.Total scores range from 13-39 with a higher score indicating better confidence in self-efficacy.

    Time frame: From enrollment to the end of the intervention at 18 months

  3. Social support

    Social support will be measured by the Multidimensional Scale of Perceived Social Support. This is a validated instrument with 12 questions rating three sources of support (family, friends, and significant others). Response options include a 7-point Likert scale ranging from 1=very strongly disagree to 7=very strongly agree. Total scores range from 12-84 with a higher score indicating stronger perceived social support.

    Time frame: From enrollment to the end of the intervention at 18 months

Secondary outcomes

  1. Hormone therapy medication side effects

    HT side effects will be assessed with the validated BCPT Symptoms Scale, which includes 25 of the most common cancer treatment symptoms, with response options using a 5-item Likert scale ranging from 0=not at all to 4=extremely. Total scores range from 0-72 with a higher score indicating more side effects experienced

    Time frame: From enrollment to the end of the intervention at 18 months

  2. Quality of life questionnaire

    Quality of life (QoL) will be measured by the Functional Assessment of Cancer Therapy-General (FACT-G) questionnaire. This questionnaire is well validated and has been used in multiple studies around the world.The FACT-G Version 4 is a 27-item, 5-point Likert scale questionnaire (0=Not at all to 4=Very much) measuring cancer patient quality of life, scoring between 0 and 108, where higher scores indicate better QoL. It is scored by reversing negatively phrased items, summing 4 subscales (Physical Well Being, Social/Family Well Being, Emotional Well Being, Functional Well Being), and requires \>80% completion.

    Time frame: From enrollment to the end of the intervention at 18 months

  3. Depression

    Depression will be assessed by the Patient Health Questionnaire (PHQ-8), an 8-item self-administered screening tool that has been validated in large clinical and population studies. Items are scored from 0=Not at all to 3=Nearly every day. Total scores range from 0-24 with a higher score indicating a higher degree of depression

    Time frame: From enrollment to the end of the intervention at 18 months

  4. Anxiety

    Anxiety will be assessed by the G 7-item scale (GAD-7), a validated tool used in clinical practice and research studies to assess the severity of anxiety. Each item is scored from 0=Not at all sure to 3=Nearly every day. Total scores range from 0-21 with a higher score indicating more anxiety.

    Time frame: From enrollment to the end of the intervention at 18 months

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2025 (actual). Primary completion is estimated for Apr 2028, 31 months after the start.

Of 180 non-industry interventional studies with no phase under Treatment Adherence and Compliance, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 36. This study's planned 31 months is above that.

Counting every sponsor, half of 185 studies reached it within 17 months; a quarter within 9 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 9, 2026
First posted
Jul 15, 2026
StartActual
Sep 26, 2025
Primary completionEst.
Apr 30, 2028
CompletionEst.
Apr 30, 2028
Last update
Jul 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07706127
Responsible party
Sponsor
First posted
Jul 15, 2026
Start date
Sep 26, 2025
Primary completion
Apr 30, 2028 (estimated)
Completion
Apr 30, 2028 (estimated)
Last update
Jul 15, 2026

Study contacts

Study Coordinator
Contact
HTHelper@uthscsa.edu
210-567-6523
Research Assistant
Contact
HTHelper@uthscsa.edu
210-567-6523
Patricia Chalela, DrPH, MPH
principal investigator · The University of Texas Health Science Center at San Antonio

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion